No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The QuilliChew ER market is a subset of the Central Nervous System (CNS) Drugs market. CNS drugs are used to treat a variety of neurological and psychiatric disorders, including depression, anxiety, and attention deficit hyperactivity disorder (ADHD). QuilliChew ER is a type of CNS drug that is used to treat ADHD in children and adolescents. It is a chewable tablet that is taken once daily and is designed to provide long-lasting symptom relief.
QuilliChew ER is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2018. It is currently available in the US, Canada, and Europe. The market for QuilliChew ER is expected to grow in the coming years as more patients are diagnosed with ADHD and seek treatment.
Some of the companies in the QuilliChew ER market include Shire Pharmaceuticals, Impax Laboratories, and Teva Pharmaceuticals. Show Less Read more
